Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced panc...
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
About this item
Full title
Author / Creator
Jo, Jung Hyun , Kim, Yong-Tae , Choi, Ho Soon , Kim, Ho Gak , Lee, Hong Sik , Choi, Young Woo , Kim, Dong Uk , Lee, Kwang Hyuck , Kim, Eui Joo , Han, Joung-Ho , Lee, Seung Ok , Park, Chang-Hwan , Choi, Eun Kwang , Kim, Jae Woo , Cho, Jae Yong , Lee, Woo Jin , Moon, Hyungsik Roger , Park, Mi-Suk , Kim, Sangjae and Song, Si Young
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background
The TeloVac study indicated GV1001 did not improve the survival of advanced pancreatic ductal adenocarcinoma (PDAC). However, the cytokine examinations suggested that high serum eotaxin levels may predict responses to GV1001. This Phase III trial assessed the efficacy of GV1001 with gemcitabine/capecitabine for eotaxin-high patients w...
Alternative Titles
Full title
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10781743
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10781743
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/s41416-023-02474-w
